文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT预测不可切除肝细胞癌90Y经动脉放射性栓塞后的生存

18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-02-23

该研究纳入48例接受90Y-TARE的不可切除肝细胞癌患者,比较治疗前18F-FDG PET/CT代谢参数与形态学影像参数的预后价值。病灶SUVmax和肿瘤/肝脏摄取比(T/L)是无进展生存和总生存的独立负性预测因子,而形态学影像参数无预测价值。

要点

  • 病灶SUVmax均值和中位数是无进展生存的显著预后标志物(均P=0.01)。
  • 病灶SUVmax和T/L摄取比的Q1切点值是总生存的显著预后标志物(均P=0.02)。
  • 多因素分析证实病灶SUVmax和T/L摄取比分别是PFS和OS的独立负性预测因子。

核心结论

  • 18F-FDG PET/CT评估的病灶SUVmax和T/L摄取比是可预测接受90Y-TARE的uHCC患者生存的标志物,而形态学影像无此预测价值。

研究设计与样本

  • 分析前瞻性数据库中48例接受90Y-TARE治疗的uHCC患者数据(31例树脂微球,17例玻璃微球)。
  • 所有患者治疗前均接受18F-FDG PET/CT和形态学影像(CT和MRI)检查,影像检查与90Y-TARE之间未接受任何治疗。
  • 采用Kaplan-Meier法评估PFS和OS,用单因素和多因素分析比较代谢参数与相关预后因素。

主要发现

  • 存活患者中位随访16.2个月(范围11.4-50.1个月)。
  • 34例(70.8%)患者在90Y-TARE后中位7.4个月(范围1.4-27.9个月)复发,34例死亡患者中24例(70.8%)在中位8.1个月(范围2.2-35.2个月)复发。
  • PFS的显著预后标志物为病灶SUVmax均値和中位数(均P=0.01;中位PFS 10.2 vs 7.4个月)。
  • OS的显著预后标志物为病灶SUVmax和T/L摄取比的Q1切点值(均P=0.02;中位OS 30.9 vs 9个月)。
  • 多因素分析显示病灶SUVmax和T/L摄取比分别是PFS(均值SUVmax HR 2.7,95%CI 1.2-6.1,P=0.02;中位数SUVmax HR 2.6,95%CI 1.1-5.9,P=0.02)和OS(Q1 SUVmax HR 3.2,95%CI 1-10.9,P=0.04;Q1 T/L摄取比 HR 3.7,95%CI 1.1-12.2,P=0.03)的独立负性预测因子。

关键数值与推荐

  • PFS的显著预后标志物:病灶SUVmax均値和中位数(均P=0.01;中位PFS 10.2 vs 7.4个月)。
  • OS的显著预后标志物:病灶SUVmax和T/L摄取比的Q1切点值(均P=0.02;中位OS 30.9 vs 9个月)。
  • PFS的独立负性预测因子:均值SUVmax(HR 2.7,95%CI 1.2-6.1,P=0.02)和中位数SUVmax(HR 2.6,95%CI 1.1-5.9,P=0.02)。
  • OS的独立负性预测因子:Q1 SUVmax(HR 3.2,95%CI 1-10.9,P=0.04)和Q1 T/L摄取比(HR 3.7,95%CI 1.1-12.2,P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the value of pretreatment functional and morphological imaging parameters for predicting survival in patients undergoing transarterial radioembolization using yttrium-90 (90Y-TARE) for unresectable hepatocellular carcinoma (uHCC). METHODS: We analysed data from 48 patients in our prospective database undergoing 90Y-TARE treatment for uHCC (31 resin, 17 glass). All patients underwent 18F-FDG PET/CT and morphological imaging (CT and MRI scans) as part of a pretherapeutic work-up. Patients did not receive any treatment between these imaging procedures and 90Y-TARE. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were used to assess the prognostic value of 18F-FDG PET/CT metabolic parameters, including SUVmax, tumour-to-liver (T/L) uptake ratio and SUVmean of healthy liver, and morphological data, including number and size of lesions, portal-venous infiltration (PVI). Relevant prognostic factors for HCC including Child-Pugh class, Barcelona Clinic Liver Cancer (BCLC) stage, tumour size, PVI and serum AFP level were compared with metabolic parameters in univariate and multivariate analyses. RESULTS: The median follow-up in living patients was 16.2 months (range 11.4-50.1 months). Relapse occurred in 34 patients (70.8%) at a median of 7.4 months (range 1.4-27.9 months) after 90Y-TARE, and relapse occurred in 24 of 34 patients (70.8%) who died from their disease at a median of 8.1 months (range 2.2-35.2 months). Significant prognostic markers for PFS were the mean and median lesion SUVmax (both P = 0.01; median PFS 10.2 vs. 7.4 months), and significant prognostic markers for OS were the first quarter (Q1) cut-off values for lesion SUVmax and T/L uptake ratio (both P = 0.02; median OS 30.9 vs. 9 months). The multivariate analysis confirmed that lesion SUVmax and T/L uptake ratio were independent negative predictors of PFS (hazard ratio, HR, 2.7, 95% CI 1.2-6.1, P = 0.02, for mean SUVmax; HR 2.6, 95% CI 1.1-5.9, P = 0.02, for median SUVmax:) and OS (HR 3.2, 95% CI 1-10.9, P = 0.04 for Q1 SUVmax; HR 3.7, 95% CI 1.1-12.2, P = 0.03, for Q1 T/L uptake ratio), respectively, when testing with either the BCLC staging system or serum AFP level. CONCLUSION: Lesion SUVmax and T/L uptake ratio as assessed by 18F-FDG PET/CT, but not morphological imaging, were predictive markers of survival in patients undergoing 90Y-TARE for uHCC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jreige M, Mitsakis P, Van Der Gucht A, et al. 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2017. PMID: 28233086. doi:10.1007/s00259-017-3653-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。